Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00021372 · ClinicalTrials.gov registry record · Phase 2
Paclitaxel and Estramustine in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
A Phase 2 study of Lymphoma, sponsored by Fox Chase Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 17
- Study locations
NCT00021372: Completed Phase 2 study of Lymphoma, sponsored by Fox Chase Cancer Center.
NCT00021372 is a Phase 2 study of Lymphoma that has completed, run by Fox Chase Cancer Center. The registered enrollment target is 25 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (95% lower). The trial reports 17 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00021372, a Phase 2 study of Lymphoma, has completed, sponsored by Fox Chase Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 17
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining paclitaxel and estramustine in treating patients who have relapsed or refractory non-Hodgkin's lymphoma.
Conditions Studied
Interventions
- DRUG paclitaxel
- DRUG estramustine phosphate sodium
Study Locations (17)
Pennsylvania
- Bon Secours-Holy Family Health System - Altoona
- Delaware County Memorial Hospital - Drexel Hill
- Pinnacle Health Hospitals - Harrisburg
- Conemaugh Memorial Hospital - Johnstown
- Saint Mary Regional Center - Langhorne
- North Penn Hospital - Lansdale
- Paoli Memorial Hospital - Paoli
- Fox Chase Cancer Center - Philadelphia
- Pottstown Memorial Regional Cancer Center - Pottstown
- Reading Hospital and Medical Center - Reading
New Jersey
- Hunterdon Regional Cancer Center - Flemington
- Kimball Medical Center - Lakewood
- South Jersey Regional Cancer Center - Millville
- Fox Chase Cancer Center at Virtua Memorial Hospital Burlington County - Mount Holly
- Riverview Medical Center - Booker Cancer Center - Red Bank
- Community Medical Center - Toms River
- St. Francis Medical Center - Trenton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 1996-02 |
| Est. Completion | 2006-09 |
| Phase | Phase 2 |
What the finished NCT00021372 record still lists
NCT00021372 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which paclitaxel is the first listed.
NCT00021372 lists 17 locations in 2 states (Pennsylvania, New Jersey).
Frequently Asked Questions
What is clinical trial NCT00021372 about?
NCT00021372 is a clinical study titled "Paclitaxel and Estramustine in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining paclitaxel and estramustine in treating patients who have...
What is the current status of trial NCT00021372?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 1996-02. Estimated completion is 2006-09.
What conditions does trial NCT00021372 study?
This clinical trial studies the following conditions: Lymphoma.
What interventions are being tested in trial NCT00021372?
The interventions under investigation include: paclitaxel (DRUG), estramustine phosphate sodium (DRUG).
Who is sponsoring clinical trial NCT00021372?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00021372 being conducted?
This trial has 17 study locations across New Jersey, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00021372's enrollment target sits among peer trials
25 230th of 299 higher than 66 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia